Scancell Holdings plc

Equities

SCLP

GB00B63D3314

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:25 2024-04-26 am EDT			5-day change	1st Jan Change
9.6 ^GBX	0.00%		0.00%	-8.57%

Mar. 26	Scancell doses first patient in melanoma-focused trials	AN
Mar. 22	Seneca Growth Capital announces tepid 2023 results	AN

Scancell doses first patient in melanoma-focused trials

March 26, 2024 at 10:03 am EDT

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

The Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases said the patient also received a combination of ipilimumab and nivolumab.

The therapeutic is a modified version of the human leukocyte antigen dependent SCIB1 used to treat melanoma patients. Scancell believes the latest version will treat a broader range of patients beyond the 40% treated with SCIB1.

Data from the latest cohort is expected in the final quarter of 2024 and, if effective, the treatment may give the company a foothold in a USD1.5 billion market.

Shares in Scancell were up 4.8% to 10.75 pence on Tuesday afternoon in London.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	TRIAL HOLDINGS INC.	2,709 JPY	+2.73%	+10.30%	2.04B
	SCANCELL HOLDINGS PLC	9.6 GBX	0.00%	0.00%	98.03M

Latest news about Scancell Holdings plc

Scancell doses first patient in melanoma-focused trials	Mar. 26	AN
Seneca Growth Capital announces tepid 2023 results	Mar. 22	AN
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board	Mar. 14	CI
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05	AN
Scancell's Chief Development Officer to Step Down	Feb. 05	MT
Scancell Holdings plc Directorate and Executive Changes Changes	Feb. 05	CI
Scancell interim loss narrows amid finance gain on derivative	Jan. 30	AN
Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2023	Jan. 30	CI
Scancell approved by MHRA to add new cohort to Scope trial	Jan. 17	AN
Scancell Holdings plc Announces Update on SCOPE Trial	Jan. 17	CI
Scancell Raises GBP1.2 Million Via Open Offer	Dec. 19	MT
Scancell raises GBP12 million in total from fundraise	Dec. 19	AN
Scancell Raises GBP11 Million via Share Issue	Dec. 01	MT
Scancell raises GBP10.7 million in upsized share sale	Dec. 01	AN
EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen	Nov. 30	AN
Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up	Nov. 28	MT
Scancell trial progresses; OptiBiotix inks new deal	Nov. 28	AN
Scancell shares up as presents "trailblazing" trial data	Nov. 10	AN
EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss	23-10-31	AN
Earnings Flash (SCLP.L) SCANCELL HOLDINGS Reports FY23 Revenue GBP5.3M	23-10-31	MT
Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2023	23-10-31	CI
Scancell says needs more time to publish annual results	23-10-20	AN
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free	23-09-28	CI
Oxford Technology 2 VCT asset value hurt by AIM share falls	23-09-22	AN
Scancell celebrates "positive" clinical trial data for cancer vaccine	23-09-19	AN

Chart Scancell Holdings plc

Duration

Period

More charts

Company Profile

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its products pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. SCIB1 is the lead product from its ImmunoBody immunotherapy platform, which identifies, attacks and destroys tumors. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - CIMT Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.096 GBP

Average target price

0.2473 GBP

Spread / Average Target

+157.64%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCANCELL HOLDINGS PLC	-8.57%	98.03M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research